What is claimed is:

1.

A treated and isolated IgG fraction, comprising: acid hydrolyzed IgG fraction which has been heated for from 15 minutes to 1 hour at a temperature of from 35°C to 40°C, and thereafter neutralized.

2.

The treated and isolated IgG fraction of claim 1 which has been hydrolyzed with from .1N to .2N acid.

3.

The treated and isolated IgG fraction of claim 2 wherein the acid is selected from the group consisting of hydrochloric acid, phosphoric acid and sulfuric acid.

4.

The treated and isolated IgG fraction of claim 1 which has a molecular weight of about 55,000.

5.

The treated and isolated IgG fraction of claim 1 wherein the IgG fraction is derived from the sources selected from the group consisting of bovine or porcine blood or colostrum, egg or whey.

6.

The treated and isolated IgG fraction of claim 5 wherein the IgG is derived from bovine blood.

7.

The treated and isolated concentrate of claim 1 which is spray dried.

8.

A method of providing bacterial static and viral static activity, comprising:

oral dosing of a mammalian species with an anti-bacterial and antiviral effective amount of a treated and isolated IgG fraction which is acid hydrolyzed, and has been heated

Sub A1

from 15 minutes to 1.0 hour at a temperature of 35°C to 40°C, and thereafter neutralized.

9.

The method of claim 8 wherein the amount dosed is sufficient to provide a dosage of 0.25 mg/ml in the mammal's gut.

10.

The method of claim 8 wherein the dose is up to 5 grams/day.